News Release

Examining association between early treatment with tocilizumab, risk of death among critically ill COVID-19 patients

Peer-Reviewed Publication

JAMA Network

What The Study Did: Whether treatment with tocilizumab in the first two days after being admitted to an intensive care unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated in this study.

Authors: David E. Leaf, M.D., M.M.Sc., of Brigham and Women's Hospital in Boston, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.